Piper Sandler Reiterates Overweight on Corcept Therapeutics, Raises Price Target to $173
Benzinga Newsdesk 10 hours ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $165 to $173.
Piper Sandler analyst David Amsellem reiterates Corcept Therapeutics (NASDAQ:CORT) with a Overweight and raises the price target from $165 to $173.